Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

ThromboGenics’ Commitment to the US Retina Community Highlighted at American Academy of Ophthalmology 2014 Meeting

14 Oct 2014

On-going ORBIT and OZONE real-world data studies with JETREA® progressing as planned

Leuven, October 14, 2014 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it will be undertaking a wide ranging program of activities to highlight the benefits of JETREA® (ocriplasmin) at the upcoming American Academy of Ophthalmology (AAO) 2014 meeting, which is taking place in Chicago from 17-21 October. The AAO meeting is the largest ophthalmology meeting in the world with more than 24,000 people expected to attend.

ThromboGenics’ activities at AAO will focus on continued medical education to help the retina community further characterize both the efficacy and safety profile of its lead drug JETREA®. The Company will host a number of expert presentations at its booth during AAO, outlining personal experiences in using this novel medicine, the first and only pharmacologic intervention approved for the treatment of symptomatic vitreomacular adhesion (VMA).

Medical affairs staff will be available to meet the retina physicians taking part, or interested in the on-going ORBIT and OZONE studies which have been designed to provide further real-world data on JETREA®. These studies are intended to help the retina community to further characterize JETREA®’s efficacy and safety profile, allowing specialists to build the proper level of confidence while treating patients suffering from symptomatic VMA. Symptomatic VMA is a progressive sight-threatening disease, which if left untreated, might lead to a macular hole and central blindness. 

Paul G. Howes, Executive Chairman of ThromboGenics Inc., said: “We plan a broad range of medical education activities at this major conference which are designed to help drive the adoption of this novel medicine. We are looking forward to further dialogue with the many retinal physicians who are taking part in the on-going ORBIT and OZONE studies as we work to generate the additional real-world data needed to ensure that JETREA® is used optimally for the benefit of the many people in the US suffering from symptomatic VMA.”

Dr Patrik De Haes, the CEO of ThromboGenics, said: “This year’s AAO meeting is another key moment for ThromboGenics as we continue to underwrite our strong commitment and continued support to the US retina community.”